SCALAMBRA, LAURA
 Distribuzione geografica
Continente #
EU - Europa 263
NA - Nord America 225
AS - Asia 190
AF - Africa 12
Totale 690
Nazione #
US - Stati Uniti d'America 225
CN - Cina 167
IT - Italia 153
DE - Germania 27
SE - Svezia 22
GB - Regno Unito 13
IE - Irlanda 12
CH - Svizzera 10
IN - India 10
FR - Francia 9
BG - Bulgaria 7
CI - Costa d'Avorio 5
HK - Hong Kong 4
JO - Giordania 4
TG - Togo 4
DK - Danimarca 3
SG - Singapore 3
AT - Austria 2
FI - Finlandia 2
HR - Croazia 2
EG - Egitto 1
JP - Giappone 1
PK - Pakistan 1
RU - Federazione Russa 1
SN - Senegal 1
ZA - Sudafrica 1
Totale 690
Città #
Shanghai 164
Bologna 36
Chandler 29
Ashburn 21
Fairfield 21
Houston 18
Woodbridge 13
Ann Arbor 12
Dublin 12
Bern 10
Cambridge 9
Milan 8
Southend 8
Kerpen 7
Sofia 7
New York 6
Princeton 6
Redmond 6
Seattle 6
Abidjan 5
Bo 5
Delhi 5
Turin 5
Vicenza 5
Wilmington 5
Amman 4
Bremen 4
Council Bluffs 4
Hong Kong 4
Lomé 4
Reggio Nell'emilia 4
Castenaso 3
Los Angeles 3
Nærum 3
Portici 3
Rome 3
Singapore 3
Boydton 2
Bühl 2
Chieti 2
Des Moines 2
Naples 2
Romainville 2
San Benedetto del Tronto 2
San Giorgio di Piano 2
Vedelago 2
Vienna 2
Alfortville 1
Candiolo 1
Cavenago Di Brianza 1
Changsha 1
Cordenons 1
Correggio 1
Costa Volpino 1
Falkenstein 1
Florence 1
Helsinki 1
Hounslow 1
Islamabad 1
Kagoya 1
Lappeenranta 1
Medford 1
Montescudo 1
Muizenberg 1
Mülheim 1
Nanjing 1
Orzinuovi 1
Pesaro 1
Phoenix 1
Reggio Emilia 1
San Diego 1
Toenisvorst 1
Weißenstadt 1
Totale 517
Nome #
IFN-γ and CD38 in Hyperprogressive Cancer Development 279
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft 223
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression 70
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC 68
Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy 44
Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine 39
Preclinical activity of ES2B-C001, a human candidate HER-2 virus-like particle (VLP) vaccine, against mammary carcinoma onset and metastasis 7
Totale 730
Categoria #
all - tutte 1.798
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.798


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021150 0 0 0 0 0 0 25 76 19 6 5 19
2021/2022118 5 7 8 8 19 21 4 4 11 9 15 7
2022/2023174 7 11 7 22 15 18 13 8 27 8 19 19
2023/2024288 10 4 22 21 17 15 9 176 4 10 0 0
Totale 730